2020 Q1 Form 10-Q Financial Statement
#000086266820000005 Filed on May 14, 2020
Income Statement
Concept | 2020 Q1 | 2019 Q3 | 2019 Q1 |
---|---|---|---|
Revenue | $2.357M | $2.288M | $2.669M |
YoY Change | -11.66% | 1.31% | 1.26% |
Cost Of Revenue | $1.281M | $1.177M | $1.398M |
YoY Change | -8.35% | -2.2% | -6.05% |
Gross Profit | $1.076M | $1.111M | $1.271M |
YoY Change | -15.31% | 5.31% | 10.73% |
Gross Profit Margin | 45.66% | 48.57% | 47.63% |
Selling, General & Admin | $903.7K | $999.4K | $1.031M |
YoY Change | -12.33% | -0.28% | -10.17% |
% of Gross Profit | 83.95% | 89.93% | 81.1% |
Research & Development | $301.0K | $245.6K | $218.0K |
YoY Change | 38.08% | 154.79% | 135.31% |
% of Gross Profit | 27.97% | 22.1% | 17.15% |
Depreciation & Amortization | $13.74K | $11.91K | -$4.550K |
YoY Change | -401.98% | -9.71% | -122.75% |
% of Gross Profit | 1.28% | 1.07% | -0.36% |
Operating Expenses | $1.205M | $1.245M | $1.249M |
YoY Change | -3.53% | 13.33% | 0.7% |
Operating Profit | -$128.3K | -$133.7K | $22.19K |
YoY Change | -678.35% | 208.21% | -124.02% |
Interest Expense | $1.718K | $3.984K | $3.995K |
YoY Change | -57.0% | -41.85% | -85.91% |
% of Operating Profit | 18.01% | ||
Other Income/Expense, Net | $424.00 | $755.1K | $20.00 |
YoY Change | 2020.0% | -17495.07% | -100.07% |
Pretax Income | -$127.9K | $621.4K | $22.21K |
YoY Change | -675.78% | -1342.74% | -118.51% |
Income Tax | |||
% Of Pretax Income | |||
Net Earnings | -$127.9K | $621.4K | $22.21K |
YoY Change | -675.92% | -1401.69% | -118.65% |
Net Earnings / Revenue | -5.42% | 27.16% | 0.83% |
Basic Earnings Per Share | -$0.02 | $0.08 | $0.00 |
Diluted Earnings Per Share | -$0.02 | $0.05 | $0.00 |
COMMON SHARES | |||
Basic Shares Outstanding | 7.415M shares | 7.415M shares | 7.415M shares |
Diluted Shares Outstanding | 7.415M shares | 12.19M shares | 12.02M shares |
Balance Sheet
Concept | 2020 Q1 | 2019 Q3 | 2019 Q1 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $695.7K | $415.8K | $528.3K |
YoY Change | 31.68% | -54.31% | -53.25% |
Cash & Equivalents | $695.6K | $415.8K | $528.3K |
Short-Term Investments | |||
Other Short-Term Assets | $134.5K | $227.7K | $263.2K |
YoY Change | -48.89% | -11.43% | 30.43% |
Inventory | $1.900M | $1.785M | $1.685M |
Prepaid Expenses | |||
Receivables | $1.114M | $1.355M | $1.623M |
Other Receivables | $0.00 | $0.00 | $0.00 |
Total Short-Term Assets | $4.100M | $4.153M | $4.352M |
YoY Change | -5.8% | -9.92% | -6.06% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $84.40K | $60.90K | $77.13K |
YoY Change | 9.42% | -18.25% | 30.14% |
Goodwill | |||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | |||
YoY Change | |||
Other Assets | $62.79K | $62.79K | |
YoY Change | |||
Total Long-Term Assets | $1.453M | $1.921M | $828.7K |
YoY Change | 75.37% | 129.82% | -0.22% |
TOTAL ASSETS | |||
Total Short-Term Assets | $4.100M | $4.153M | $4.352M |
Total Long-Term Assets | $1.453M | $1.921M | $828.7K |
Total Assets | $5.553M | $6.074M | $5.180M |
YoY Change | 7.19% | 11.53% | -5.17% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $680.5K | $691.4K | $675.1K |
YoY Change | 0.81% | 1.82% | -7.23% |
Accrued Expenses | $683.4K | $619.4K | $760.3K |
YoY Change | -10.11% | -16.76% | -37.78% |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $201.6K | $201.6K | $201.6K |
YoY Change | 0.0% | 0.0% | 18.57% |
Long-Term Debt Due | $3.130K | $3.490K | $3.340K |
YoY Change | -6.29% | ||
Total Short-Term Liabilities | $2.597M | $2.432M | $2.272M |
YoY Change | 14.3% | 4.76% | -1.87% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $12.64K | $13.98K | $15.77K |
YoY Change | -19.85% | -30.1% | -16.35% |
Other Long-Term Liabilities | $962.8K | $844.5K | $723.9K |
YoY Change | 33.01% | 14.12% | -5.99% |
Total Long-Term Liabilities | $975.5K | $858.5K | $739.6K |
YoY Change | 31.89% | 12.91% | -6.05% |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $2.597M | $2.432M | $2.272M |
Total Long-Term Liabilities | $975.5K | $858.5K | $739.6K |
Total Liabilities | $3.573M | $3.290M | $3.012M |
YoY Change | 18.62% | 6.77% | -2.93% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$68.37M | -$67.57M | -$68.19M |
YoY Change | 0.28% | -0.62% | 0.28% |
Common Stock | $7.415K | $7.415K | $7.415K |
YoY Change | 0.0% | 0.0% | -1.8% |
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $1.980M | $2.784M | $2.169M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $5.553M | $6.074M | $5.180M |
YoY Change | 7.19% | 11.53% | -5.17% |
Cashflow Statement
Concept | 2020 Q1 | 2019 Q3 | 2019 Q1 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$127.9K | $621.4K | $22.21K |
YoY Change | -675.92% | -1401.69% | -118.65% |
Depreciation, Depletion And Amortization | $13.74K | $11.91K | -$4.550K |
YoY Change | -401.98% | -9.71% | -122.75% |
Cash From Operating Activities | $465.0K | $7.166K | -$122.7K |
YoY Change | -479.09% | -39.44% | -134.08% |
INVESTING ACTIVITIES | |||
Capital Expenditures | -$2.910K | $0.00 | $0.00 |
YoY Change | -100.0% | ||
Acquisitions | |||
YoY Change | |||
Other Investing Activities | $0.00 | ||
YoY Change | |||
Cash From Investing Activities | -$2.910K | -$9.390K | $0.00 |
YoY Change | 44.33% | ||
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | |||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | -860.0 | -$822.00 | -800.0 |
YoY Change | 7.5% | -102.28% | -97.33% |
NET CHANGE | |||
Cash From Operating Activities | 465.0K | $7.166K | -122.7K |
Cash From Investing Activities | -2.910K | -$9.390K | 0.000 |
Cash From Financing Activities | -860.0 | -$822.00 | -800.0 |
Net Change In Cash | 461.3K | $6.344K | -123.5K |
YoY Change | -473.58% | -84.67% | -137.42% |
FREE CASH FLOW | |||
Cash From Operating Activities | $465.0K | $7.166K | -$122.7K |
Capital Expenditures | -$2.910K | $0.00 | $0.00 |
Free Cash Flow | $467.9K | $7.166K | -$122.7K |
YoY Change | -481.46% | -67.18% | -134.08% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
dei |
Amendment Flag
AmendmentFlag
|
false | ||
dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--06-30 | ||
dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q3 | ||
dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2020 | ||
dei |
Document Period End Date
DocumentPeriodEndDate
|
2020-03-31 | ||
dei |
Document Type
DocumentType
|
10-Q | ||
dei |
Entity Central Index Key
EntityCentralIndexKey
|
0000862668 | ||
CY2020Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2020Q1 | us-gaap |
Assets
Assets
|
5552950 | USD |
CY2019Q2 | us-gaap |
Assets Current
AssetsCurrent
|
4260921 | USD |
CY2020Q1 | us-gaap |
Assets Current
AssetsCurrent
|
4099563 | USD |
CY2018Q2 | us-gaap |
Cash
Cash
|
1124002 | USD |
CY2019Q1 | us-gaap |
Cash
Cash
|
780628 | USD |
CY2019Q2 | us-gaap |
Cash
Cash
|
662878 | USD |
CY2020Q1 | us-gaap |
Cash
Cash
|
950740 | USD |
CY2018Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
874002 | USD |
CY2019Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
528280 | USD |
CY2020Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
7415329 | shares |
dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | ||
dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | ||
dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | ||
dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
No | ||
dei |
Entity Registrant Name
EntityRegistrantName
|
ESCALON MEDICAL CORP. | ||
dei |
Entity Shell Company
EntityShellCompany
|
false | ||
dei |
Entity Small Business
EntitySmallBusiness
|
true | ||
CY2019Q3 | esmc |
Accruedinterestrelatedparty
Accruedinterestrelatedparty
|
112389 | USD |
esmc |
Increasedecreaseinliabilitiesofdiscontinuedoperations
Increasedecreaseinliabilitiesofdiscontinuedoperations
|
-2444 | USD | |
esmc |
Increasedecreaseinliabilitiesofdiscontinuedoperations
Increasedecreaseinliabilitiesofdiscontinuedoperations
|
-2933 | USD | |
CY2020Q1 | esmc |
Interestportioninthefutureleasepayments
Interestportioninthefutureleasepayments
|
158424 | USD |
esmc |
Maximum Maturity Of Highly Liquid Investments Period
MaximumMaturityOfHighlyLiquidInvestmentsPeriod
|
P90D | ||
CY2020Q1 | esmc |
Netpresentvalueofnewleasefuturepayments
Netpresentvalueofnewleasefuturepayments
|
1247470 | USD |
CY2019Q4 | esmc |
Newleaseliabilities
Newleaseliabilities
|
285000 | USD |
esmc |
Pp Ploanamount
PPPloanamount
|
500000 | USD | |
CY2019Q2 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
666510 | USD |
CY2020Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
680531 | USD |
CY2019Q2 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
1496105 | USD |
CY2020Q1 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
1114037 | USD |
CY2019Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
656707 | USD |
CY2020Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
683409 | USD |
CY2019Q2 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
69702043 | USD |
CY2020Q1 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
69702043 | USD |
CY2020Q1 | us-gaap |
Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
|
111000 | USD |
CY2019Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
213000 | shares |
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
4815527 | shares | |
CY2020Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
5246239 | shares |
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
5246239 | shares | |
CY2019Q2 | us-gaap |
Assets
Assets
|
5127438 | USD |
CY2019Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
409743 | USD |
CY2020Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
695648 | USD |
CY2018Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
1124002 | USD |
CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
780628 | USD |
CY2019Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
662878 | USD |
CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
950740 | USD |
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-343374 | USD | |
us-gaap |
Interest Paid Net
InterestPaidNet
|
42242 | USD | |
us-gaap |
Interest Paid Net
InterestPaidNet
|
12515 | USD | |
CY2019Q2 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
112389 | USD |
CY2020Q1 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
112389 | USD |
CY2019Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
287862 | USD | |
us-gaap |
Common Stock Conversion Basis
CommonStockConversionBasis
|
4300000 | ||
CY2019Q1 | us-gaap |
Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
|
234000 | USD |
CY2019Q2 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
426803 | USD |
CY2020Q1 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
543415 | USD |
CY2018Q3 | us-gaap |
Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
|
709000 | USD |
CY2020Q1 | us-gaap |
Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
|
240000 | USD |
us-gaap |
Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
|
718000 | USD | |
CY2019Q2 | us-gaap |
Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Discount Rate
DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
|
0.045 | |
CY2019Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
35000000 | shares |
CY2020Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
35000000 | shares |
CY2019Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
7415329 | shares |
CY2020Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
7415329 | shares |
CY2019Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
7415329 | shares |
CY2020Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
7415329 | shares |
CY2019Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
7415 | USD |
CY2020Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
7415 | USD |
us-gaap |
Common Stock Voting Rights
CommonStockVotingRights
|
0.7781 | ||
CY2019 | us-gaap |
Concentration Risk Credit Risk Financial Instruments
ConcentrationRiskCreditRiskFinancialInstruments
|
0.10 | |
us-gaap |
Concentration Risk Credit Risk Financial Instruments
ConcentrationRiskCreditRiskFinancialInstruments
|
0.10 | ||
us-gaap |
Concentration Risk Customer
ConcentrationRiskCustomer
|
0.1 | ||
us-gaap |
Concentration Risk Customer
ConcentrationRiskCustomer
|
0.1 | ||
CY2019Q1 | us-gaap |
Convertible Preferred Dividends Net Of Tax
ConvertiblePreferredDividendsNetOfTax
|
12723 | USD |
us-gaap |
Convertible Preferred Dividends Net Of Tax
ConvertiblePreferredDividendsNetOfTax
|
39018 | USD | |
CY2020Q1 | us-gaap |
Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
|
2.15 | shares |
CY2019Q1 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
1397693 | USD |
us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
3880999 | USD | |
CY2020Q1 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
1280995 | USD |
us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
3909844 | USD | |
CY2020Q1 | us-gaap |
Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
|
0.01 | |
CY2018Q2 | us-gaap |
Deferred Revenue
DeferredRevenue
|
481000 | USD |
CY2018Q3 | us-gaap |
Deferred Revenue
DeferredRevenue
|
465000 | USD |
CY2019Q1 | us-gaap |
Deferred Revenue
DeferredRevenue
|
440000 | USD |
CY2019Q2 | us-gaap |
Deferred Revenue
DeferredRevenue
|
427000 | USD |
CY2019Q3 | us-gaap |
Deferred Revenue
DeferredRevenue
|
636000 | USD |
CY2020Q1 | us-gaap |
Deferred Revenue
DeferredRevenue
|
543000 | USD |
CY2018Q3 | us-gaap |
Deferred Revenue Additions
DeferredRevenueAdditions
|
668000 | USD |
CY2019Q1 | us-gaap |
Deferred Revenue Additions
DeferredRevenueAdditions
|
209000 | USD |
CY2020Q1 | us-gaap |
Deferred Revenue Additions
DeferredRevenueAdditions
|
147000 | USD |
us-gaap |
Deferred Revenue Additions
DeferredRevenueAdditions
|
834000 | USD | |
CY2019Q2 | us-gaap |
Deposits Assets Noncurrent
DepositsAssetsNoncurrent
|
51915 | USD |
CY2020Q1 | us-gaap |
Deposits Assets Noncurrent
DepositsAssetsNoncurrent
|
62786 | USD |
us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
20381 | USD | |
us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
37206 | USD | |
us-gaap |
Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
|
0 | USD | |
CY2019Q2 | us-gaap |
Dividends Payable Amount Per Share
DividendsPayableAmountPerShare
|
0.04 | |
CY2020Q1 | us-gaap |
Dividends Payable Amount Per Share
DividendsPayableAmountPerShare
|
0.0549 | |
CY2018Q1 | us-gaap |
Dividends Payable Amount Per Share
DividendsPayableAmountPerShare
|
0.03 | |
CY2019Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.00 | |
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.04 | ||
CY2020Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.02 | |
CY2020Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0 | |
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.03 | ||
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.04 | ||
CY2019Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.00 | |
CY2020Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.02 | |
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.03 | ||
us-gaap |
Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
|
0 | USD | |
us-gaap |
Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
|
758021 | USD | |
CY2020Q1 | us-gaap |
Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
|
0.3670 | |
CY2019Q2 | us-gaap |
Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
|
189790 | USD |
CY2020Q1 | us-gaap |
Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
|
257720 | USD |
CY2019Q2 | us-gaap |
Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
|
188755 | USD |
CY2020Q1 | us-gaap |
Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
|
256121 | USD |
CY2019Q2 | us-gaap |
Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
|
256311 | USD |
CY2020Q1 | us-gaap |
Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
|
325285 | USD |
CY2019Q2 | us-gaap |
Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
|
272881 | USD |
CY2020Q1 | us-gaap |
Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
|
339925 | USD |
CY2019Q2 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
141700 | USD |
CY2020Q1 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
126962 | USD |
us-gaap |
Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
|
0 | USD | |
us-gaap |
Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
|
605005 | USD | |
CY2019Q1 | us-gaap |
Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
|
0 | USD |
us-gaap |
Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
|
0 | USD | |
CY2020Q1 | us-gaap |
Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
|
0 | USD |
us-gaap |
Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
|
605006 | USD | |
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
146232 | USD | |
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
14021 | USD | |
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
235784 | USD | |
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-382068 | USD | |
us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-114135 | USD | |
us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
97291 | USD | |
us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-41313 | USD | |
us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
116612 | USD | |
us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-138430 | USD | |
us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
21408 | USD | |
us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
0 | USD | |
us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
-10872 | USD | |
us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
13597 | USD | |
us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-88560 | USD | |
us-gaap |
Increase Decrease In Pension And Postretirement Obligations
IncreaseDecreaseInPensionAndPostretirementObligations
|
-25613 | USD | |
us-gaap |
Increase Decrease In Pension And Postretirement Obligations
IncreaseDecreaseInPensionAndPostretirementObligations
|
-33964 | USD | |
CY2019Q1 | us-gaap |
Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
|
4602527 | shares |
us-gaap |
Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
|
0 | shares | |
CY2020Q1 | us-gaap |
Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
|
0 | shares |
us-gaap |
Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
|
0 | shares | |
CY2019Q2 | us-gaap |
Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
|
605006 | USD |
CY2020Q1 | us-gaap |
Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
|
0 | USD |
CY2019Q1 | us-gaap |
Interest Expense
InterestExpense
|
3995 | USD |
us-gaap |
Interest Expense
InterestExpense
|
14268 | USD | |
CY2020Q1 | us-gaap |
Interest Expense
InterestExpense
|
1718 | USD |
us-gaap |
Interest Expense
InterestExpense
|
9821 | USD | |
us-gaap |
Line Of Credit Facility Periodic Payment Interest
LineOfCreditFacilityPeriodicPaymentInterest
|
13243 | USD | |
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-2522 | USD | |
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-6506 | USD | |
CY2019Q2 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
779000 | USD |
CY2020Q1 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
864000 | USD |
CY2019Q2 | us-gaap |
Inventory Net
InventoryNet
|
1878860 | USD |
CY2019Q2 | us-gaap |
Inventory Net
InventoryNet
|
1879000 | USD |
CY2020Q1 | us-gaap |
Inventory Net
InventoryNet
|
1900000 | USD |
CY2020Q1 | us-gaap |
Inventory Net
InventoryNet
|
1900268 | USD |
CY2019Q2 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
875000 | USD |
CY2020Q1 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
793000 | USD |
CY2019Q2 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
225000 | USD |
CY2020Q1 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
243000 | USD |
CY2019Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
4015 | USD |
us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
7389 | USD | |
CY2020Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
792 | USD |
us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
3632 | USD | |
us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
350000 | USD | |
CY2020Q1 | us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
99570 | USD |
us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
308468 | USD | |
us-gaap |
Lessee Operating Lease Lease Not Yet Commenced Residual Value Guarantee Description
LesseeOperatingLeaseLeaseNotYetCommencedResidualValueGuaranteeDescription
|
119815 | ||
CY2019Q4 | us-gaap |
Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
|
P5Y | |
CY2019Q3 | us-gaap |
Lessor Operating Lease Term Of Contract
LessorOperatingLeaseTermOfContract
|
P12M | |
CY2019Q2 | us-gaap |
Liabilities
Liabilities
|
2965199 | USD |
CY2020Q1 | us-gaap |
Liabilities
Liabilities
|
3572564 | USD |
CY2019Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
5127438 | USD |
CY2020Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
5552950 | USD |
CY2019Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
2260209 | USD |
CY2020Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
2597099 | USD |
CY2019Q2 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
704990 | USD |
CY2020Q1 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
975465 | USD |
CY2019Q2 | us-gaap |
Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
|
90933 | USD |
CY2020Q1 | us-gaap |
Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
|
88000 | USD |
CY2020Q1 | us-gaap |
Line Of Credit Facility Fair Value Of Amount Outstanding
LineOfCreditFacilityFairValueOfAmountOutstanding
|
201575 | USD |
CY2020Q1 | us-gaap |
Line Of Credit Facility Interest Rate At Period End
LineOfCreditFacilityInterestRateAtPeriodEnd
|
0.0399 | |
CY2019Q1 | us-gaap |
Line Of Credit Facility Periodic Payment Interest
LineOfCreditFacilityPeriodicPaymentInterest
|
3627 | USD |
CY2020Q1 | us-gaap |
Line Of Credit Facility Periodic Payment Interest
LineOfCreditFacilityPeriodicPaymentInterest
|
1500 | USD |
us-gaap |
Line Of Credit Facility Periodic Payment Interest
LineOfCreditFacilityPeriodicPaymentInterest
|
8842 | USD | |
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
34489 | USD | |
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-38971 | USD | |
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-371357 | USD | |
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
329355 | USD | |
CY2018Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-47736 | USD |
CY2018Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-217983 | USD |
CY2019Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
22205 | USD |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-243514 | USD | |
CY2019Q3 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
962823 | USD |
CY2020Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
962823 | USD |
CY2019Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
621373 | USD |
CY2019Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-675343 | USD |
CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-127883 | USD |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-181853 | USD | |
CY2019Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
9482 | USD |
us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-282249 | USD | |
CY2020Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-140889 | USD |
us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-220871 | USD | |
CY2019Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
22205 | USD |
us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-282249 | USD | |
CY2020Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-127883 | USD |
us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-181853 | USD | |
CY2019Q1 | us-gaap |
Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
|
9482 | USD |
us-gaap |
Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
|
-282249 | USD | |
CY2020Q1 | us-gaap |
Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
|
-140889 | USD |
us-gaap |
Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
|
-220871 | USD | |
CY2019Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
20 | USD |
us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
4243 | USD | |
CY2020Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
424 | USD |
us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
753182 | USD | |
CY2019Q1 | us-gaap |
Operating Costs And Expenses
OperatingCostsAndExpenses
|
2646485 | USD |
us-gaap |
Operating Costs And Expenses
OperatingCostsAndExpenses
|
7593690 | USD | |
CY2020Q1 | us-gaap |
Operating Costs And Expenses
OperatingCostsAndExpenses
|
2485690 | USD |
us-gaap |
Operating Costs And Expenses
OperatingCostsAndExpenses
|
8320299 | USD | |
CY2019Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
22185 | USD |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-247757 | USD | |
CY2020Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-128307 | USD |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-935035 | USD | |
CY2019Q3 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
1208000 | USD |
CY2019Q2 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
0 | USD |
CY2019Q3 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
284647 | USD |
CY2020Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
284647 | USD |
CY2019Q2 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
0 | USD |
CY2019Q2 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
0 | USD |
CY2019Q3 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
1179240 | USD |
CY2020Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
1179240 | USD |
CY2019Q3 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
1137878 | USD |
CY2019Q3 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
1138000 | USD |
CY2020Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0 | |
CY2020Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P4Y3M18D | |
CY2019Q2 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
1360981 | USD |
CY2020Q1 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
1405894 | USD |
CY2019Q2 | us-gaap |
Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
|
96830 | USD |
CY2020Q1 | us-gaap |
Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
|
131214 | USD |
us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
2086 | USD | |
CY2019Q2 | us-gaap |
Operating Leases Future Minimum Payments Receivable Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsReceivableRemainderOfFiscalYear
|
356414 | USD |
CY2020Q1 | us-gaap |
Operating Leases Future Minimum Payments Receivable Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsReceivableRemainderOfFiscalYear
|
95629 | USD |
CY2019Q2 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
223078 | USD |
CY2020Q1 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
134518 | USD |
us-gaap |
Other Income
OtherIncome
|
758000 | USD | |
CY2019Q2 | us-gaap |
Other Long Term Notes Payable
OtherLongTermNotesPayable
|
14896 | USD |
CY2020Q1 | us-gaap |
Other Long Term Notes Payable
OtherLongTermNotesPayable
|
12642 | USD |
CY2019Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
0 | USD |
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
11122 | USD | |
CY2020Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
1350 | USD |
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
759371 | USD | |
CY2019Q2 | us-gaap |
Other Notes Payable Current
OtherNotesPayableCurrent
|
3401 | USD |
CY2020Q1 | us-gaap |
Other Notes Payable Current
OtherNotesPayableCurrent
|
3133 | USD |
us-gaap |
Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
|
0 | USD | |
us-gaap |
Payments For Leasing Costs
PaymentsForLeasingCosts
|
0 | USD | |
us-gaap |
Payments For Leasing Costs
PaymentsForLeasingCosts
|
245700 | USD | |
us-gaap |
Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
|
6506 | USD | |
us-gaap |
Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
|
38971 | USD | |
CY2019Q2 | us-gaap |
Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Current And Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrentAndNoncurrent
|
791985 | USD |
us-gaap |
Pension And Other Postretirement Benefit Contributions
PensionAndOtherPostretirementBenefitContributions
|
8491 | USD | |
CY2019Q2 | us-gaap |
Pension And Other Postretirement Defined Benefit Plans Current Liabilities
PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
|
101891 | USD |
CY2020Q1 | us-gaap |
Pension And Other Postretirement Defined Benefit Plans Current Liabilities
PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
|
0 | USD |
CY2019Q2 | us-gaap |
Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
|
690094 | USD |
CY2020Q1 | us-gaap |
Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
|
0 | USD |
CY2019 | us-gaap |
Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
|
70968 | USD |
us-gaap |
Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
|
109986 | USD | |
CY2019Q1 | us-gaap |
Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
|
12723 | USD |
us-gaap |
Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
|
38735 | USD | |
CY2020Q1 | us-gaap |
Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
|
13006 | USD |
us-gaap |
Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
|
39018 | USD | |
CY2019Q2 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
CY2020Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
CY2019Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
2000000 | shares |
CY2020Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
2000000 | shares |
CY2019Q2 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
2000000 | shares |
CY2020Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
2000000 | shares |
CY2018Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
2000000 | shares |
CY2019Q2 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
645000 | USD |
CY2020Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
645000 | USD |
us-gaap |
Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
|
36575 | USD | |
us-gaap |
Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
|
-2522 | USD | |
CY2019Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
67896 | USD |
CY2020Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
84399 | USD |
CY2017Q3 | us-gaap |
Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
|
645000 | USD |
CY2018Q1 | us-gaap |
Related Party Transaction Due From To Related Party
RelatedPartyTransactionDueFromToRelatedParty
|
645000 | USD |
us-gaap |
Related Party Transaction Rate
RelatedPartyTransactionRate
|
0.0125 | ||
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
7415329 | shares | |
CY2019Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
12017856 | shares |
us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
0 | USD | |
CY2019Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
218014 | USD |
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
540760 | USD | |
CY2020Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
301029 | USD |
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
808426 | USD | |
CY2018Q2 | us-gaap |
Restricted Cash
RestrictedCash
|
250000 | USD |
CY2019Q1 | us-gaap |
Restricted Cash
RestrictedCash
|
252348 | USD |
CY2019Q2 | us-gaap |
Restricted Cash
RestrictedCash
|
253135 | USD |
CY2020Q1 | us-gaap |
Restricted Cash
RestrictedCash
|
255092 | USD |
CY2019Q2 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
253135 | USD |
CY2020Q1 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
255092 | USD |
CY2019Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-68192219 | USD |
CY2020Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-68374072 | USD |
CY2019Q1 | us-gaap |
Revenues
Revenues
|
2668670 | USD |
us-gaap |
Revenues
Revenues
|
7345933 | USD | |
CY2020Q1 | us-gaap |
Revenues
Revenues
|
2357383 | USD |
us-gaap |
Revenues
Revenues
|
7385264 | USD | |
CY2019Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
1030778 | USD |
us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
3171931 | USD | |
CY2020Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
903666 | USD |
us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
2997023 | USD | |
CY2019Q2 | us-gaap |
Short Term Borrowings
ShortTermBorrowings
|
201575 | USD |
CY2020Q1 | us-gaap |
Short Term Borrowings
ShortTermBorrowings
|
201575 | USD |
CY2020Q1 | us-gaap |
Short Term Lease Payments
ShortTermLeasePayments
|
95375 | USD |
us-gaap |
Short Term Lease Payments
ShortTermLeasePayments
|
296004 | USD | |
CY2018Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
2412255 | USD |
CY2018Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
2364519 | USD |
CY2018Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
2146536 | USD |
CY2019Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
2168741 | USD |
CY2019Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
2162239 | USD |
CY2019Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
2783612 | USD |
CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
2108269 | USD |
CY2020Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1980386 | USD |
CY2020Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
7415329 | shares |
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
7415329 | shares | |
CY2019Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
7415329 | shares |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
7415329 | shares | |
CY2020Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
7415329 | shares |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
7415329 | shares | |
us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">          Escalon Medical Corp. ("Escalon" or "Company") is a Pennsylvania corporation initially incorporated in California in 1987, and reincorporated in Pennsylvania in November 2001. Within this document, the “Company” collectively shall mean Escalon, which includes its division called "Trek" and its wholly owned subsidiaries: Sonomed, Inc. (“Sonomed”), Escalon Digital Solutions, Inc. (“EMI”), Escalon Holdings, Inc. (“EHI”), Escalon IP Holdings, Inc., and Sonomed IP Holdings, Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in the healthcare market, specializing in the development, manufacture, marketing and distribution of medical devices and pharmaceuticals in the area of ophthalmology. The Company and its products are subject to regulation and inspection by the United States Food and Drug Administration (the “FDA”). The FDA and other government authorities require extensive testing of new products prior to sale and have jurisdiction over the safety, efficacy and manufacture of products, as well as product labeling and marketing.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The unaudited condensed consolidated financial statements included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission, and reflect all adjustments (consisting of only normal and recurring adjustments) which are, in the opinion of management, necessary to present fairly the unaudited condensed consolidated financial information required herein. Certain information and note disclosures normally included in financial statement prepared in accordance with accounting principles generally accepted in the United Statements of America ("US GAAP") have been condensed or omitted pursuant to such rules and regulations. While management believes that the disclosures are adequate to make the information presented not misleading, it is suggested that these unaudited condensed consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in the Company's Annual Report on Form 10-K filed with the Security and Exchange Commission for the fiscal year ended June 30, 2019. The results of operations for the nine-month period ended March 31, 2020 are not necessarily indicative of the results to be expected for the full year. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">    </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 11, 2020, the World Health Organization declared the outbreak of a coronavirus (COVID-19) a pandemic. This pandemic has had a significant impact on the global and domesitc economy, and is likely to impact the operations of the Company. The Company has been assessing the impact of the COVID-19 pandemic on the business, including the impact on the financial condition and results of operations, financial resources, changes in accounting judgment as well as the impact on the supply and demand, etc. The Company is considered an essential business and has been able to maintain operations during the lockdown. The Company applied for and received </font><font style="font-family:inherit;font-size:10pt;">$500,000</font><font style="font-family:inherit;font-size:10pt;"> in April 2020 under the Payroll Protection Program (PPP loan) which will help reverse the negative impact in terms of the liquidity. The maturity date is two years from the date of the note. The interest rate is </font><font style="font-family:inherit;font-size:10pt;">1.00%</font><font style="font-family:inherit;font-size:10pt;"> per year. The Company remains in strong communications with the customers and there is no evidence showing that COVID-19 will greatly effect collection of accounts receivable as of date of this filing. There is no indication of any write-down of inventory as of date of this filing, such as decline in the market value of inventory despite a decrease of the sales in the lock down period. However, the Company does not know the extent and duration of the impact of COVID-19 on its business due to the uncertainty about the spread of the virus. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The Company’s common stock trades on the OTCQB Market under the symbol “ESMC.”</font></div></div> | ||
us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Reclassifications</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lease deposits of </font><font style="font-family:inherit;font-size:10pt;">$51,915</font><font style="font-family:inherit;font-size:10pt;"> in the June 30, 2019 consolidated balance sheet has been reclassed from other current assets to the other assets be conformity with the current period presentation.</font></div></div> | ||
us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with accounting principles generally affected in the US GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</font></div></div> |